References of "Franceschi, M"
     in
Bookmark and Share    
See detailHeterogeneity of brain glucose metabolism in mild cognitive impairment and clinical progression to Alzheimer disease
Anchisi, D.; Borroni, B.; Franceschi, M. et al

in Archives of Neurology (2005), 62(11), 1728-1733

Background: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk for progression to Alzheimer disease (AD) and a population with different underlying pathologic ... [more ▼]

Background: Subjects with amnesic mild cognitive impairment (aMCI) may include patients at high risk for progression to Alzheimer disease (AD) and a population with different underlying pathologic conditions. Objective: To evaluate the potential roles of positron emission tomography with fluodeoxyglucose F 18 ((18)FDG-PET) and memory scores in identifying subjects with aMCI and in predicting progression to dementia. Design, Setting, and Patients: Sixty-seven patients at European centers for neurologic and AD care who were diagnosed as having aMCI each underwent an extensive clinical and neuropsychological examination and an (18)FDG-PET study. Forty-eight subjects were followed up periodically for at least I year, and progression to dementia was evaluated. Main Outcome Measures: Brain glucose metabolism and memory scores. Results: Fourteen subjects with aMCI who converted to AD within 1 year showed bilateral hypometabolism in the inferior parietal, posterior cingulate, and medial temporal cortex. Subjects with "stable" aMCI presented with hypometabolism in the dorsolateral frontal cortex. The severity of memory impairment, as evaluated by the California Verbal Learning Test-Long Delay Free Recall scores, correlated with the following brain metabolic patterns: scores less than 7 were associated with a typical (18)FDG-PET AD pattern, and scores of 7 or higher were associated with hypornetabolism in the dorsolateral frontal cortex and no progression to AD. Conclusion: These data provide evidence for clinical and functional heterogeneity among subjects with aMCI and suggest that (18)FDG-PET findings combined with memory scores may be useful in predicting short-term conversion to AD. [less ▲]

Detailed reference viewed: 28 (1 ULiège)
Full Text
Peer Reviewed
See detailMCI conversion to dementia and the APOE genotype : A prediction study with FDG-PET
Mosconi, L.; Perani, D.; Sorbi, S. et al

in Neurology (2004), 63(12), 2332-2340

Objectives: To investigate whether the combination of fluoro-2-deoxy-D-glucose (FDG) PET measures with the APOE genotype would improve prediction of the conversion from mild cognitive impairment (MCI) to ... [more ▼]

Objectives: To investigate whether the combination of fluoro-2-deoxy-D-glucose (FDG) PET measures with the APOE genotype would improve prediction of the conversion from mild cognitive impairment (MCI) to Alzheimer disease ( AD). Method: After 1 year, 8 of 37 patients with MCI converted to AD (22%). Differences in baseline regional glucose metabolic rate (rCMRglc) across groups were assessed on a voxel-based basis using a two-factor analysis of variance with outcome (converters [n = 8] vs nonconverters [n = 29]) and APOE genotype (E4 carriers [E4+] [n = 16] vs noncarriers [E4-] [n = 21]) as grouping factors. Results were considered significant at p < 0.05, corrected for multiple comparisons. Results: All converters showed reduced rCMRglc in the inferior parietal cortex (IPC) as compared with the nonconverters. Hypometabolism in AD-typical regions, that is, temporoparietal and posterior cingulate cortex, was found for the E4+ as compared with the E4- patients, with the E4+/converters (n = 5) having additional rCMRglc reductions within frontal areas, such as the anterior cingulate (ACC) and inferior frontal (IFC) cortex. For the whole MCI sample, IPC rCMRglc predicted conversion to AD with 84% overall diagnostic accuracy (p = 0.003). Moreover, ACC and IFC rCMRglc improved prediction for the E4+ group, yielding 100% sensitivity, 90% specificity, and 94% accuracy (p < 0.0005), thus leading to an excellent discrimination. Conclusion: Fluoro-2-deoxy-D-glucose-PET measures may improve prediction of the conversion to Alzheimer disease, especially in combination with the APOE genotype. [less ▲]

Detailed reference viewed: 60 (0 ULiège)